Ginlix AI
50% OFF

Iluvatar CoreX (09903.HK): MACD Golden Cross Analysis and Short-Term Buy Value Assessment

#技术分析 #港股 #GPU #半导体 #IPO #股票分析 #MACD
Neutral
A-Share
January 12, 2026

Unlock More Features

Login to access AI-powered analysis, deep research reports and more advanced features

Iluvatar CoreX (09903.HK): MACD Golden Cross Analysis and Short-Term Buy Value Assessment

About us: Ginlix AI is the AI Investment Copilot powered by real data, bridging advanced AI with professional financial databases to provide verifiable, truth-based answers. Please use the chat box below to ask any financial question.

Related Stocks

09903
--
09903
--

Based on my analysis, below is the MACD Golden Cross Analysis and Short-Term Buy Value Assessment for Iluvatar CoreX (09903.HK):


Iluvatar CoreX (09903.HK) Technical Analysis Report
1. Stock Overview

Iluvatar CoreX
was officially listed on the main board of the Hong Kong Stock Exchange (HKEX) on January 8, 2026, becoming a rare pure-play general GPU target in the Hong Kong stock market[1]. As the first Chinese enterprise to achieve mass production of general GPUs, the company is known as one of the “Four Little Dragons of Domestic GPUs” along with Biren Technology, Muxi Semiconductor, and Moore Thread[2].

Item Data
Offer Price HK$144.6
First-Day Opening Price HK$190.2 (+31.54%)
First-Day Closing Price HK$156.8 (+8.44%)
Latest Closing Price (Approx.) HK$167.5 (as of January 12)
Current Increase +15.84%
Market Capitalization Approx. HK$40 Billion
2. MACD Indicator Analysis

Important Note
: As Iluvatar CoreX just listed on January 8, 2026, there are only 4 trading days of historical data available for technical analysis, making the data sample extremely limited. The following is a preliminary analysis based on limited data:

Indicator Value Interpretation
MACD Line 2.50 Above the Signal Line
Signal Line 1.77 -
MACD Histogram +0.73 Positive and expanding
2-Day Moving Average HK$166.35 Stock price is above the moving average
3-Day Moving Average HK$164.40 Stock price is above the moving average

MACD Golden Cross Judgment
: Currently, the MACD line is above the Signal Line, and the histogram is positive, indicating a short-term bullish trend[0]. However, due to insufficient data (only 4 trading days),
the validity of the golden cross signal cannot be confirmed
, and more trading day data is needed to verify the reliability of the signal.

3. Short-Term Buy Value Assessment
Positive Factors
  1. Bullish Moving Average System
    : The current stock price (HK$167.5) has broken above the 2-day and 3-day moving averages, with short-term moving averages trending upward[0]
  2. High Market Popularity
    : The IPO received 414 times oversubscription, indicating high recognition from the capital market[1]
  3. Solid Fundamentals
    : The compound annual growth rate (CAGR) of revenue from 2022 to 2024 reached 68.8%, and the revenue in the first half of 2025 was RMB 324 million, a year-on-year increase of 64.2%[2]
  4. Technological Leadership
    : The first domestic enterprise to achieve mass production of inference and training general GPU chips[3]
Risk Factors
  1. High Volatility for New Stock
    : The stock fell sharply from the intraday high of HK$190.2 to HK$156.8 on the first day of listing[1]
  2. Declining Trading Volume
    : Trading volume has gradually decreased from 15 million shares on the first day to 6.8 million shares, indicating weakening upward momentum[0]
  3. Relatively High Absolute Stock Price
    : The stock price of over HK$160 may limit retail investor participation
  4. Sustained Losses
    : The cumulative loss from 2022 to the first half of 2025 was approximately RMB 2.87 billion[1]
4. Operation Recommendations
Strategy Type Recommendation
Short-Term (1-2 Weeks)
Insufficient data to support the validity of the MACD golden cross; it is recommended to wait and see for more confirmed technical signals
Medium-Term (1-3 Months)
Consider accumulating on dips if the stock price pulls back to the HK$140-150 range
Risk-Taking Investors
May participate with a small position, and set a strict stop-loss (below HK$150)
5. Target Price Reference

Based on market analysis, as a leader in the domestic GPU track, some analysts have given Iluvatar CoreX a

target price range of HK$275-315
[4], representing significant upside potential from the current price.

6. Conclusion

From the perspective of the MACD golden cross, Iluvatar CoreX

does not have a clear short-term buy signal
for the following reasons:

  1. Insufficient data sample, unable to confirm the validity of the golden cross
  2. Trading volume is on a declining trend, with upward momentum weakening
  3. High volatility in the initial stage of listing, requiring time to establish an equilibrium price

However, from a mid-to-long-term perspective, the domestic GPU track where the company operates has huge import substitution potential. In addition, the company has achieved large-scale mass production and has a solid customer base, giving it good mid-to-long-term investment value. It is recommended that investors maintain attention and wait for clearer technical patterns before making decisions.


References

[1] Sina Finance - “Surge of 31.54%! Iluvatar CoreX Lists on HKEX” (https://finance.sina.com.cn/roll/2026-01-08/doc-inhfqpsv1366092.shtml)

[2] Securities Times - “Iluvatar CoreX Officially Lists on HKEX, Enters the Main Battlefield of Domestic GPU Stock Substitution” (https://www.stcn.com/article/detail/3578117.html)

[3] AAStocks - “HK Stock Movement | Iluvatar CoreX Rises Over 32% on Debut” (https://www.aastocks.com/tc/stocks/analysis/stock-aafn-con/09903/GLH/GLH2244581L/hk-stock-news)

[4] East Money Caifuhao - “Iluvatar CoreX Rises Up to 45.23%, Is This the End? No, It’s Still Undervalued!” (https://caifuhao.eastmoney.com/news/20260107182842169170760)

Related Reading Recommendations
No recommended articles
Ask based on this news for deep analysis...
Alpha Deep Research
Auto Accept Plan

Insights are generated using AI models and historical data for informational purposes only. They do not constitute investment advice or recommendations. Past performance is not indicative of future results.